Pharmaceutical company Cannabis Science has announced two distinct drug development paths for clinical trials, including new treatments for H1N5 avian flu and H1N1 swine flu.

The company has also identified research into treating post-traumatic stress disorder (PTSD) in war veterans as the second product development path to be developed for US Food and Drug Administration (FDA) trials.

To treat flu virus strains, the company intends to develop products that mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry.

Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances and cardiovascular disease.

Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.

The Veterans PTSD programme will test the efficacy of a cannabis extract-based oral medicine.

The first step, to be carried out at the State University of New York, will consist of a survey to monitor the use of medical marijuana in veterans with PTSD.

Cannabis Science president and CEO Dr Robert Melamede said that modern science supports the public demand for cannabis-based FDA-approved drug products that reduce the impact of critical life-altering illnesses.

“We are sourcing compliant facilities to produce our initial formulations for FDA compliant-testing,” Melamede said.

The company believes these initiatives will lay a solid foundation for entrance into the FDA and other government regulatory agencies for developing medicines for influenza, PTSD and other ailments.